Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
By S. Buys, E. Partridge, A. Black, Christine C. Johnson, L. Lamerato, C. Isaacs, D. Reding, R. Greenlee, L. Yokochi, B. Kessel and 21 more. Journal of the American Medical Association (JAMA), 2011
1,225 citations recorded by the source corpus.
Subfields: Epidemiology, Obstetrics and Gynecology, Reproductive Medicine
View Paper: https://www.semanticscholar.org/paper/53d111cddf54c8dc91b2b7ca799cc3ae07d33fb4
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Obstetrics and Gynecology
In Reproductive Medicine
Citations in the corpus
- Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk (2015, background): “As yet, no EOC screening or early detection strategies have been proven useful in general population [2].”
- Loss of BRCA1 in the cells of origin of ovarian cancer induces glycolysis: A window of opportunity for ovarian cancer chemoprevention (2017, background): “Unfortunately, screening for ovarian cancer is ineffective (3); therefore, to prevent ovarian cancer, clinical guidelines recommend that BRCA1mutation carriers have their fallopian tubes and ovaries removed between the ages of 35 and 40 years (4).”
- Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening (2018, neutral): “In 2011, the PLCO RCT report on ovarian cancer screening with CA 125 and TVU concluded that simultaneous screening with a fixed threshold of CA 125 and TVU, compared with usual care, did not reduce ovarian cancer mortality.(99) Based largely on the PLCO results, the USPSTF recommended against screen”